Sentiment for Omeros Corp (NASDAQ:OMER)
Omeros Corp (NASDAQ:OMER) institutional sentiment increased to 1.35 in Q2 2019. Its up 0.35, from 1 in 2019Q1. The ratio increased, as 50 investment managers started new and increased stock positions, while 37 reduced and sold holdings in Omeros Corp. The investment managers in our partner’s database now hold: 24.08 million shares, down from 24.17 million shares in 2019Q1. Also, the number of investment managers holding Omeros Corp in their top 10 stock positions was flat from 1 to 1 for the same number . Sold All: 7 Reduced: 30 Increased: 35 New Position: 15.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $758.16 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.
The stock increased 6.05% or $0.87 during the last trading session, reaching $15.24. About 1.30M shares traded or 221.43% up from the average. Omeros Corporation (NASDAQ:OMER) has declined 24.60% since December 4, 2018 and is downtrending. It has underperformed by 24.60% the S&P500.
Analysts await Omeros Corporation (NASDAQ:OMER) to report earnings on March, 6. They expect $-0.30 EPS, up 21.05 % or $0.08 from last year’s $-0.38 per share. After $-0.33 actual EPS reported by Omeros Corporation for the previous quarter, Wall Street now forecasts -9.09 % EPS growth.
Ingalls & Snyder Llc holds 3.75% of its portfolio in Omeros Corporation for 4.97 million shares. Consonance Capital Management Lp owns 3.05 million shares or 3.39% of their US portfolio. Moreover, Rocky Mountain Advisers Llc has 0.8% invested in the company for 15,035 shares. The Massachusetts-based Capital Impact Advisors Llc has invested 0.62% in the stock. American Financial Group Inc, a Ohio-based fund reported 340,284 shares.
Omeros Corporation (NASDAQ:OMER) Ratings Coverage
Ratings analysis reveals 50% of Omeros Corporation’s analysts are positive. Out of 2 Wall Street analysts rating Omeros Corporation, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $18 while the high is $3400. The stock’s average target of $26 is 70.60% above today’s ($15.24) share price. OMER was included in 4 notes of analysts from October 13, 2019. The firm has “Buy” rating by H.C. Wainwright given on Monday, December 2. The rating was maintained by Wedbush with “Hold” on Monday, November 4.
More notable recent Omeros Corporation (NASDAQ:OMER) news were published by: Globenewswire.com which released: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation – OMER – GlobeNewswire” on November 11, 2019, also Businesswire.com with their article: “Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy – Business Wire” published on November 08, 2019, Finance.Yahoo.com published: “Is Omeros Corporation’s (NASDAQ:OMER) CEO Paid At A Competitive Rate? – Yahoo Finance” on May 29, 2019. More interesting news about Omeros Corporation (NASDAQ:OMER) were released by: Finance.Yahoo.com and their article: “Calls Pop as Drug Stock Gets FDA Boost – Yahoo Finance” published on July 11, 2019 as well as Benzinga.com‘s news article titled: “46 Biggest Movers From Yesterday – Benzinga” with publication date: November 05, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.